Cubist Systematic Strategies, LLC Actinium Pharmaceuticals, Inc. Transaction History
Cubist Systematic Strategies, LLC
- $20.3 Billion
- Q2 2025
A detailed history of Cubist Systematic Strategies, LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 1,927 shares of ATNM stock, worth $2,909. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,927Holding current value
$2,909% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
7MCall Options Held
39.2KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.37MShares$2.07 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny663KShares$1 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA492KShares$742,8330.0% of portfolio
-
Geode Capital Management, LLC Boston, MA330KShares$497,8300.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $38M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...